Glycomimetics, Inc. (GLYC)

Trade GLYC now with
11/6/2020 7:40:09 AM GlycoMimetics Q3 Loss Per Share $0.29 Vs Loss $0.31 Last Year
10/26/2020 9:04:54 AM GlycoMimetics Announces That New Post Hoc Analyses Of The Phase 3 RESET Study
4/7/2020 9:18:07 AM GlycoMimetics Appoints Myra Rosario Herrle As VP, Regulatory Affairs
2/28/2020 8:10:39 AM GlycoMimetics Q4 Loss/shr Widens To $0.34 From $0.32 Prior Year
2/4/2020 9:57:20 AM GlycoMimetics Announces Several Achievements For Its GMI-1359 Development Program
1/6/2020 9:09:03 AM GlycoMimetics And Apollomics To Develop And Commercialize Uproleselan And GMI-1687 In China
4/12/2019 9:12:57 AM GlycoMimetics Plans To Initiate Clinical Trial Of GMI-1359 In Breast Cancer Patients Whose Tumors Have Spread To Bone
11/2/2018 7:45:45 AM GlycoMimetics Q3 Loss Per Share $0.27 Vs Loss $0.24 Last Year
5/30/2018 9:20:34 AM GlycoMimetics Signs Cooperative Research And Development Agreement With The National Cancer Institute
5/3/2018 7:19:06 AM GlycoMimetics Posts Q1 Net Loss Of $11.51 Mln Or $0.33/share
3/20/2018 9:38:59 PM GlycoMimetics Announces Pricing Of Underwritten Public Offering Of 7 Mln Shares At $17.00/shr
3/19/2018 4:03:29 PM GlycoMimetics Announces Proposed Public Offering Of Common Stock
3/6/2018 7:34:58 AM GlycoMimetics Q4 Loss Per Share $0.27 Vs Loss $0.36 Last Year